Targeting vulnerable Dengue epitopes: Characterization of broadly neutralizing antibodies and engineering novel epitope-focusing immunogens
针对脆弱的登革热表位:广泛中和抗体的表征和工程新型表位聚焦免疫原
基本信息
- 批准号:9758214
- 负责人:
- 金额:$ 4.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-01 至 2020-05-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntibodiesAntibody ResponseAntibody-Dependent EnhancementAntigensAntiviral AgentsApplications GrantsAttenuated Live Virus VaccineBindingBiological Response Modifier TherapyCapsidComputer SimulationCrystallizationDNADataDengueDengue VaccineDengue VirusDevelopmentDimerizationDirected Molecular EvolutionDiseaseE proteinEngineeringEnvironmentEpitopesExhibitsFellowshipFlavivirusGTP-Binding Protein alpha Subunits, GsGeometryGoalsHealthHospitalizationHumoral ImmunitiesImmuneImmune responseImmunoglobulin GIn VitroIncidenceIndividualInfectionKnowledgeLengthLinkLinker DNAMeasuresMembrane FusionMentorshipMethodsModelingMolecular ConformationMonoclonal AntibodiesMutagenesisNIH Program AnnouncementsNational Research Service AwardsPeptidesPrimary InfectionProcessProtein EngineeringProteinsResearch PersonnelRiskRoleSerotypingStructureSumSurfaceTherapeuticTrainingVaccinationVaccine DesignVaccinesViralVirionVirusVirus-like particleYeastsantibody engineeringarmbasecareercross reactivitydesigndimerexperimental studyglobal healthimmunogenicityin vivoin vivo evaluationinsightmouse modelneutralizing antibodynovelparticlepre-doctoralpreventresponserisk minimizationsynthetic antibodiestherapeutic developmenttoolvaccine candidatevaccine development
项目摘要
Project summary/abstract
This grant application responds to Program Announcement Number PA-18-671 (Ruth L. Kirschstein NRSA
Individual Predoctoral Fellowship) by proposing protein engineering and computational protein design strategies
to target vulnerable epitopes of Dengue virus, focusing on the E dimer epitope (EDE) and the DIII A/G strand
epitope. Dengue virus, comprising 4 distinct serotypes, is a growing health threat with ~390 million new infections
yearly. Infection with one Dengue serotype confers lifelong protection against the same serotype, yet heterotypic
infections are associated with severe disease as cross-reactive, non-neutralizing humoral immunity may
exacerbate infection via antibody-dependent enhancement (ADE). An effective vaccine must thus elicit robust
and broadly-neutralizing antibody responses to provide protection and minimize risk of ADE.
We will characterize and define effects, namely binding valency, relevant to potent neutralization by
antibodies targeting the EDE. Preliminary observations suggest that some EDE antibodies may be unable to
bind the virus bivalently, which is contrary to the otherwise frequent observation that IgGs’ gain their potency by
binding viral capsids bivalently. We propose engineering synthetic diFabs – two Fabs connected by DNA linkers
– to augment the reach of the IgG’s two binding moieties. We will characterize binding and neutralization
potencies of diFabs with linkers of varying lengths to define conditions that afford bivalent binding and perhaps
greater neutralization potency. Exploring the ability for bivalent engagement of Dengue virions and engineering
molecules capable of doing so has the potential to lend insight into effective neutralization mechanisms.
We will also develop and characterize epitope-focusing immunogens based on the DIII A/G strand and EDE.
In a mouse model, we will determine the in vivo immunogenicity profiles of resurfaced DIII immunogens, which
we have engineered to maintain the A/G strand epitope and eliminate loops known to be associated with narrow
or non-neutralizing responses. Neutralization activity, breadth, and relative contributions of cross-reactive or
serotype-specific responses, will be determined. As soluble E does not readily dimerize, we will also engineer a
single-chain E dimer immunogen via a computational rewiring method. Further resurfacing will be completed via
a data-driven approach, using antibodies known to be associated with protective/enhancing responses to identify
regions to be eliminated via mutagenesis while maintaining the EDE. In sum, the components of this proposal
have the potential to contribute to our knowledge of neutralizing responses to Dengue thus advancing therapeutic
and vaccine development.
During this project, the PI Jennifer Lai will be trained in protein engineering and computational protein design
methods. Notably, the PI will have the opportunity to carry out various stages – in silico design, in vitro/in vivo
evaluations of antigenicity/immunogenicity – of vaccine development. Mentorship within a collegial environment
will enable the PI’s professional development towards a career as an independent investigator and educator.
项目总结/文摘
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Combinatorial resurfacing of Dengue envelope protein domain III antigens selectively ablates epitopes associated with serotype-specific or infection-enhancing antibody responses.
- DOI:10.1021/acscombsci.0c00073
- 发表时间:2020-06
- 期刊:
- 影响因子:0
- 作者:Jennifer L Remmel;K. Beauchemin;Akaash K. Mishra;Julia C. Frei;J. Lai;C. Bailey-Kellogg;M. Ackerman
- 通讯作者:Jennifer L Remmel;K. Beauchemin;Akaash K. Mishra;Julia C. Frei;J. Lai;C. Bailey-Kellogg;M. Ackerman
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jennifer I. Lai其他文献
Assembly and disassembly of Aspergillus fumigatus conidial rodlets
烟曲霉分生孢子小棒的组装和拆卸
- DOI:
10.1016/j.tcsw.2019.100023 - 发表时间:
2019 - 期刊:
- 影响因子:0
- 作者:
I. Valsecchi;Jennifer I. Lai;Emmanuel Stephen;A. Pillé;A. Beaussart;Victor Lo;Chi L.L. Pham;V. Aimanianda;Ann H. Kwan;Magalie Duchateau;Quentin Giai Gianetto;M. Matondo;M. Lehoux;Donald C. Sheppard;Yves F. Dufrêne;J. Bayry;J. I. Guijarro;M. Sunde;J. Latgé - 通讯作者:
J. Latgé
Jennifer I. Lai的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 4.5万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 4.5万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 4.5万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 4.5万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 4.5万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 4.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 4.5万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 4.5万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 4.5万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 4.5万 - 项目类别:














{{item.name}}会员




